Baidu
map

NEJM:视网膜中央静脉阻塞案例报道

2015-11-13 chenshuo 译 MedSci原创

男性,43岁,以往有高血压病史,近日突发出现左眼视力受损而入院就诊。 视力测量发现,其只能在3英尺的距离上计数手指数目。眼内压测量值为20mmHg(处于正常范围的上限)。

男性,43岁,以往有高血压病史,近日突发出现左眼视力受损而入院就诊。


视力测量发现,其只能在3英尺的距离上计数手指数目。眼内压测量值为20mmHg(处于正常范围的上限)。



眼底镜检查可见明显右眼视神经“视杯”现象(如图A,箭头处)、视神经的充血和肿胀(如图B,箭头处)、弥漫性黄斑水肿、视网膜内出血以及左眼视网膜静脉迂曲扩张(如图B,箭头处)。

根据该男子的临床表现与检查结果,主治医生诊断为左眼中央静脉阻塞和双侧原发性开角型青光眼。

对于本病例,要注意与其他的一些突发无痛性视力丧失进行鉴别诊断,包括玻璃体出血、视网膜动脉或静脉阻塞、视网膜脱离、缺血性视神经病变和枕叶卒中等。

一般情况下,视网膜中央静脉阻塞往往是突发性无痛性视力丧失最常见的原因。但是,也要考虑到其他的危险因素存在导致,包括高龄、高血压、青光眼和糖尿病等。当患者的发病年龄较小时,应注意考虑患者本身是否有炎症或凝血功能障碍。

最后,该男子使用马来酸噻吗洛尔滴眼液和抗高血压药物进行治疗。在接下来的8个月的跟踪随访期间,该男子的视力恢复到20/200,黄斑处水肿明显改善。

原始出处:

Abtin Shahlaee,and Jayanth Sridhar.Central Retinal-Vein Occlusion.N Engl J Med .November 12, 2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697274, encodeId=d6be169e274ee, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 21 08:36:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801536, encodeId=fb7c180153685, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 22 00:36:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696660, encodeId=af3a169666080, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Mar 12 03:36:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269810, encodeId=68de1269810c9, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 14 15:36:00 CST 2015, time=2015-11-14, status=1, ipAttribution=)]
    2016-04-21 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697274, encodeId=d6be169e274ee, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 21 08:36:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801536, encodeId=fb7c180153685, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 22 00:36:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696660, encodeId=af3a169666080, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Mar 12 03:36:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269810, encodeId=68de1269810c9, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 14 15:36:00 CST 2015, time=2015-11-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697274, encodeId=d6be169e274ee, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 21 08:36:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801536, encodeId=fb7c180153685, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 22 00:36:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696660, encodeId=af3a169666080, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Mar 12 03:36:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269810, encodeId=68de1269810c9, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 14 15:36:00 CST 2015, time=2015-11-14, status=1, ipAttribution=)]
    2016-03-12 tomyang96
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697274, encodeId=d6be169e274ee, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 21 08:36:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801536, encodeId=fb7c180153685, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun May 22 00:36:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696660, encodeId=af3a169666080, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sat Mar 12 03:36:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269810, encodeId=68de1269810c9, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 14 15:36:00 CST 2015, time=2015-11-14, status=1, ipAttribution=)]
    2015-11-14 zutt

相关资讯

笹井芳树:培养皿中长出视网膜

撰文:笹井芳树(Yoshiki Sasai)制图:布莱恩·克里斯蒂(Bryan Christie)翻译:冷颖琳 科学家已经可以诱导干细胞形成视网膜,这为很多眼疾患者带来希望。 在子宫里,一团相同的细胞分化成各种不同的模样,最终形成高度有序的结构,组装成人体的全副器官。这个过程依照内在的“生物学蓝图”有条不紊地进行,引导组织产生折叠、皱褶,精确形成适当的外形和大小。 科

J Nerosci:你是我的眼:视网膜变性疾病如何让人失去光明

发表在国际杂志The Journal of Neuroscience上的一篇研究论文中,来自蒙特利尔临床研究学院的科学家揭开了一项重大的研究突破,研究人员在视网膜中发现了一种关键蛋白,其在感光细胞的生存和功能发挥中扮演着重要角色,感光细胞对于视觉非常关键,该研究为揭示视网膜变性疾病引发失明的分子机制提供了一定的线索。 文章中,研究者研究了一种名为区室作用的过程,该过程可以在细胞中建立并且维持

J Clin Periodonto:牙周炎和视网膜微循环在动脉粥样硬化中的风险

J Clin Periodonto:牙周炎和视网膜微循环在动脉粥样硬化中的风险关键词:牙周炎 视网膜 微循环在发达国家,牙周疾病(PDs)几乎影响了50%的30岁以上人群。PDs是细菌引起的炎症性疾病,累及支持牙齿的软硬组织。牙根表面的菌斑生物膜是始动因子,破坏牙周结缔组织和牙槽骨。如果不治疗PDs,病情继续发展,最终结果是牙齿脱落。慢性牙周炎是PDs最常见的一种类型,与许多全身状况有关,包括血

Sci Transl Med:基因疗法让患者重见光明

我们对视觉皮层在视觉障碍,视觉恢复及与环境的相互作用的可塑性的理解大多来源于动物实验。本研究中我们评估了一组Leber先天性黑朦患者(LCA),通过基因治疗恢复了视力。通过非侵入性的多模态神经影像学方法,我们证实了基因治疗可逆转失明,加强了大脑中视觉通路的结构可塑性。研究数据显示,与LCA患者未经治疗的眼睛视觉通路相比,接受携带治疗基因载体注射治疗的眼睛的视网膜位点,其相应的视网膜纤维发生改善并正

PLoS One:从孕妇的眼睛里看到胎儿的生长

Li LJ等人近期进行了一项有趣的研究,探究孕中期母体视网膜微脉管系统情况与胎儿宫内生长和出生时大小的关系。该研究共纳入732名单胎妊娠、孕早期、18-46岁的孕妇,在26-28周孕时对母体行视网膜眼底照相,同时行胎儿B超检查记录头围等生长数据。接着在32-34周孕对胎儿行B超检查再次记录生长数据。当胎儿出生时对其测量生长发育参数。用计算机软件对视网膜眼底照相进行处理分析,得到视网膜微脉管系统相关

后生可畏,拜耳眼科药物Eylea第4个适应症获欧盟批准

拜耳(Bayer)及合作伙伴再生元(Regeneron)近日宣布,眼科药物(aflibercept,阿柏西普注射液)在欧盟收获第4个适应症。欧盟委员会(EC)已批准Eylea用于视网膜静脉阻塞继发黄斑水肿(RVO-ME)的治疗,包括视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)及先前已获批的视网膜中央静脉阻塞继发黄斑水肿(CRVO-ME)。建议的治疗方法为:起始治疗时每周注射一次直至达到最大

Baidu
map
Baidu
map
Baidu
map